FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2971323891> ?p ?o ?g. }

• W2971323891 endingPage "3131" @default.
• W2971323891 startingPage "3124" @default.
• W2971323891 abstract "PURPOSE Although chemoradiation therapy (CRT) with cisplatin remains the standard treatment of patients with locally advanced cervical cancer (LACC), 40% of patients present with disease recurrence. Additional treatment strategies are required to improve outcomes. We conducted a trial to evaluate the efficacy and safety of neoadjuvant chemotherapy (NAC) with cisplatin and gemcitabine followed by CRT. METHODS In this phase II trial, patients with LACC (International Federation of Gynecology and Obstetrics stage IIB to IVA or with positive lymph nodes) were randomly assigned to three cycles of NAC with cisplatin and gemcitabine followed by standard CRT with weekly cisplatin plus pelvic radiotherapy or to standard CRT alone. The primary end point was 3-year progression-free survival (PFS). Secondary end points were response rate, 3-year locoregional control, 3-year overall survival (OS), safety, and quality of life. RESULTS From 107 patients enrolled in the trial, 55 were randomly assigned to the NAC arm and 52 to the CRT-alone arm. The majority of patients had squamous cell carcinoma (87.8%). After a median follow-up of 31.7 months, NAC was associated with an inferior PFS, with 3-year PFS rates of 40.9% v 60.4% in the CRT arm (hazard ratio, 1.84; 95% CI, 1.04 to 3.26; P = .033). NAC also was associated with a lower OS (3-year OS rate, 60.7% v 86.8%; hazard ratio, 2.79; 95% CI, 1.29 to 6.01; P = .006). After treatment completion, complete response rates were 56.3% in the NAC arm and 80.3% in the CRT arm ( P = .008). Toxicities were similar in both arms, with the exception of hypomagnesemia and neuropathy being more common with NAC. CONCLUSION This study shows that the addition of NAC consisting of cisplatin and gemcitabine to standard CRT is not superior and is possibly inferior to CRT alone for the treatment of LACC." @default.
• W2971323891 created "2019-09-05" @default.
• W2971323891 creator A5002925742 @default.
• W2971323891 creator A5014565080 @default.
• W2971323891 creator A5029172851 @default.
• W2971323891 creator A5050678857 @default.
• W2971323891 creator A5050884175 @default.
• W2971323891 creator A5053333915 @default.
• W2971323891 creator A5066337859 @default.
• W2971323891 creator A5071477903 @default.
• W2971323891 creator A5074617492 @default.
• W2971323891 creator A5079522026 @default.
• W2971323891 creator A5084420695 @default.
• W2971323891 creator A5084889695 @default.
• W2971323891 creator A5089700411 @default.
• W2971323891 date "2019-11-20" @default.
• W2971323891 modified "2023-10-10" @default.
• W2971323891 title "Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial" @default.
• W2971323891 cites W1592737438 @default.
• W2971323891 cites W1965860066 @default.
• W2971323891 cites W2014166989 @default.
• W2971323891 cites W2036097821 @default.
• W2971323891 cites W2042026763 @default.
• W2971323891 cites W2070266241 @default.
• W2971323891 cites W2100756525 @default.
• W2971323891 cites W2104360894 @default.
• W2971323891 cites W2118508302 @default.
• W2971323891 cites W2133787749 @default.
• W2971323891 cites W2147016542 @default.
• W2971323891 cites W2158244375 @default.
• W2971323891 cites W2170091237 @default.
• W2971323891 cites W2314753133 @default.
• W2971323891 cites W2324392028 @default.
• W2971323891 cites W2417185998 @default.
• W2971323891 cites W2480089904 @default.
• W2971323891 cites W2511010656 @default.
• W2971323891 cites W2575889113 @default.
• W2971323891 cites W2734796223 @default.
• W2971323891 cites W2889646458 @default.
• W2971323891 cites W4298106286 @default.
• W2971323891 doi "https://doi.org/10.1200/jco.19.00674" @default.
• W2971323891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31449470" @default.
• W2971323891 hasPublicationYear "2019" @default.
• W2971323891 type Work @default.
• W2971323891 sameAs 2971323891 @default.
• W2971323891 citedByCount "60" @default.
• W2971323891 countsByYear W29713238912019 @default.
• W2971323891 countsByYear W29713238912020 @default.
• W2971323891 countsByYear W29713238912021 @default.
• W2971323891 countsByYear W29713238912022 @default.
• W2971323891 countsByYear W29713238912023 @default.
• W2971323891 crossrefType "journal-article" @default.
• W2971323891 hasAuthorship W2971323891A5002925742 @default.
• W2971323891 hasAuthorship W2971323891A5014565080 @default.
• W2971323891 hasAuthorship W2971323891A5029172851 @default.
• W2971323891 hasAuthorship W2971323891A5050678857 @default.
• W2971323891 hasAuthorship W2971323891A5050884175 @default.
• W2971323891 hasAuthorship W2971323891A5053333915 @default.
• W2971323891 hasAuthorship W2971323891A5066337859 @default.
• W2971323891 hasAuthorship W2971323891A5071477903 @default.
• W2971323891 hasAuthorship W2971323891A5074617492 @default.
• W2971323891 hasAuthorship W2971323891A5079522026 @default.
• W2971323891 hasAuthorship W2971323891A5084420695 @default.
• W2971323891 hasAuthorship W2971323891A5084889695 @default.
• W2971323891 hasAuthorship W2971323891A5089700411 @default.
• W2971323891 hasConcept C121608353 @default.
• W2971323891 hasConcept C126322002 @default.
• W2971323891 hasConcept C141071460 @default.
• W2971323891 hasConcept C143998085 @default.
• W2971323891 hasConcept C168563851 @default.
• W2971323891 hasConcept C203092338 @default.
• W2971323891 hasConcept C207103383 @default.
• W2971323891 hasConcept C2776694085 @default.
• W2971323891 hasConcept C2778220009 @default.
• W2971323891 hasConcept C2778239845 @default.
• W2971323891 hasConcept C2778424827 @default.
• W2971323891 hasConcept C2780258809 @default.
• W2971323891 hasConcept C44249647 @default.
• W2971323891 hasConcept C71924100 @default.
• W2971323891 hasConceptScore W2971323891C121608353 @default.
• W2971323891 hasConceptScore W2971323891C126322002 @default.
• W2971323891 hasConceptScore W2971323891C141071460 @default.
• W2971323891 hasConceptScore W2971323891C143998085 @default.
• W2971323891 hasConceptScore W2971323891C168563851 @default.
• W2971323891 hasConceptScore W2971323891C203092338 @default.
• W2971323891 hasConceptScore W2971323891C207103383 @default.
• W2971323891 hasConceptScore W2971323891C2776694085 @default.
• W2971323891 hasConceptScore W2971323891C2778220009 @default.
• W2971323891 hasConceptScore W2971323891C2778239845 @default.
• W2971323891 hasConceptScore W2971323891C2778424827 @default.
• W2971323891 hasConceptScore W2971323891C2780258809 @default.
• W2971323891 hasConceptScore W2971323891C44249647 @default.
• W2971323891 hasConceptScore W2971323891C71924100 @default.
• W2971323891 hasIssue "33" @default.
• W2971323891 hasLocation W29713238911 @default.
• W2971323891 hasLocation W29713238912 @default.
• W2971323891 hasOpenAccess W2971323891 @default.
• W2971323891 hasPrimaryLocation W29713238911 @default.

• next